Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Cangfu Daotan Granule is a Traditional Chinese Medicine (TCM) formulation developed by the Maternal and Child Health Hospital of Hubei Province. It is specifically designed for the treatment of polycystic ovary syndrome (PCOS) and associated infertility, particularly in patients categorized under the phlegm-dampness TCM syndrome. The formula is a modification of the classic Cangfu Daotan Decoction, which traditionally aims to dry dampness, resolve phlegm, and regulate Qi. In the context of PCOS, it is used to regulate the hypothalamic-pituitary-ovarian (HPO) axis, improve insulin sensitivity, and lower serum androgen levels, thereby promoting follicular development and ovulation. As a hospital preparation, it is manufactured and prescribed within the specific clinical setting of the developing institution.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Cangfu Daotan granule.